Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML

Table 3

OS according to the RDI received in consolidation.

	Median survival with a 2-years follow-up
<0.75 ()	9.33 (0.00–24.15)
>0.75 ()	24.00 (15.82–32.18)
	0.266